Targeting Root Causes of Obesity and Metabolic Disease with Harith Rajagopalan Fractyl Health TRANSCRIPT
Download PDFJul 8, 2026
Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage. Unlike...
Jul 8, 2026
Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage. Unlike...
Reformulating Diabetes Drug to Treat Degenerative Eye Diseases with Richard Garr Curative Biotechnology TRANSCRIPT
Download PDFJul 6, 2026
Richard Garr, CEO and General Counsel of Curative Biotechnology, discusses the company's work in repurposing the diabetes drug metformin into an eye drop for degenerative eye diseases. The goal of the therapy is retinal preservation, aiming to slow or stop disease progression by acting at the cellular level in the back...
Novel Precision Gene Therapy for Friedreich’s Ataxia with Dr. Gabriel Brooks Solid Biosciences TRANSCRIPT
Download PDFApr 23, 2026
Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic...
Apr 23, 2026
Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic...